Rakovina Therapeutics Inc. has reported progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (ataxia telangiectasia and Rad3-related) inhibitors designed to disrupt ...

Your morning coffee may offer more than just a quick jolt of alertness. New research from Queen Mary University of London reveals caffeine's remarkable ability to extend the lifespan of cells by ...

Cryo-EM reconstructions of the human ATR–ATRIP complex show how clinical small-molecule inhibitors like VE-822 and RP-3500 bind to and inhibit ATR activity. A research team led by Prof. Gang Cai and ...

Phase 1 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2024 ...

Thus, the phase 3 TOPAZ-1 trial (NCT03875235) made big news in 2021 when it met its primary overall survival (OS) end point in an interim analysis. Among patients with newly diagnosed advanced BTC, ...

It has been previously demonstrated that while cancer cells with defects in ataxia telangiectasia mutated kinase (ATM) signaling are susceptible to ataxia telangiectasia and Rad3-related (ATR) ...

Several new clinical trials in gynecologic cancers have started enrolling recently. Perhaps one of your patients is eligible to take part? Persistent or recurrent endometrial cancer or any advanced ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will regain global development and commercialization ...

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.” Glioblastoma cells can restrict the DNA-damaging ...

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

Urologic cancers such as kidney, bladder, prostate, and uroepithelial cancers have recently become a considerable global health burden, and the response to immunotherapy is limited due to immune ...